Published in
American Society of Hematology, Blood Advances, 19(3), p. 2836-2844, 2019
DOI: 10.1182/bloodadvances.2019000627
Links
Tools
Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy
Journal article published in 2019 by
Scott R. Solomon,
Andrew St. Martin,
Nirav N. Shah,
Giancarlo Fatobene 
,
Monzr M. Al Malki,
Karen K. Ballen,
Asad Bashey,
Nelli Bejanyan,
Javier Bolaños Meade,
Claudio G. Brunstein,
Zachariah DeFilipp ,
Richard E. Champlin ,
Ephraim J. Fuchs,
Mehdi Hamadani ,
Peiman Hematti
and other authors.
,
Monzr M. Al Malki,
Karen K. Ballen,
Asad Bashey,
Nelli Bejanyan,
Javier Bolaños Meade,
Claudio G. Brunstein,
Zachariah DeFilipp ,
Richard E. Champlin ,
Ephraim J. Fuchs,
Mehdi Hamadani ,
Peiman Hematti
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Disease-free survival is higher with myeloablative regimens for patients in their third to fifth decade. Beyond the fifth decade, low-dose total body irradiation regimens offset mortality associated with transplant procedure.